Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2020 · 10-Q
Revenue$0.00$0.00no prior Q3 2019 on file Net Income-$2.88M-$2.88MN/M vs Q3 2019 EPS Diluted-$0.64-$0.64N/M vs Q3 2019 Operating Income-$1,945,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
derived
ended Sep 30, 2020 · filed Nov 13, 2020 · 44 d after period end